Results 61 to 70 of about 10,605 (184)

IgE-Related Chronic Diseases and Anti-IgE-Based Treatments

Journal of Immunology Research, 2016
IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies ...
Arnau Navinés-Ferrer, Eva Serrano-Candelas, Gustavo-J Molina-Molina, Margarita Martín   +3 more
doaj   +1 more source

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

Фармакоэкономика, 2020
Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods.
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev   +2 more
doaj   +1 more source

Treatment Persistence and Factors Associated With Discontinuation in Real‐World Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Biologic therapies are effective for severe, uncontrolled CRSwNP, yet real‐world data on treatment persistence remain limited. Methods This retrospective single‐center study included 95 adults with CRSwNP who initiated dupilumab (88.4%), mepolizumab, or omalizumab between 2021 and 2025.
Hen Chaushu, Yuval Presman, Roni Vass, Narin Nard Carmel‐Neiderman, Liyona Kampel, Forsan Jahashan, Nidal Muhanna, Eiman Abu Bandora, Avraham Abergel   +8 more
wiley   +1 more source

Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab can provide clinical benefits to a fraction of moderate-to-severe asthma patients. However, the mechanisms of action of omalizumab have not been fully understood.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Mark Millard, MD, Matthew Wiest, PhD, Chao Gu, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma

Frontiers in Immunology
IntroductionPatients with severe asthma may benefit from targeted biological therapies. However, personalized therapy in children and adolescents with asthma, based on individual susceptibility to molecular mechanisms addressed by different biologicals ...
Boris Gole, Larisa Goričan, Gregor Jezernik, Mario Gorenjak, Anja Bizjak, Vojko Berce, Vojko Berce, Maja Skerbinjek Kavalar, Michael Kabesch, Erik Melén, Korneliusz Golebski, Cornelius M. van Drunen, Anke Hilse Maitland-van der Zee, Anke Hilse Maitland-van der Zee, Susanne Reinartz, Susanne J. H. Vijverberg, Susanne J. H. Vijverberg, Uroš Potočnik, Uroš Potočnik, Uroš Potočnik   +19 more
doaj   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study

Allergology International, 2018
Background: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double ...
Michihiro Hide, Atsuyuki Igarashi, Akiko Yagami, Yuko Chinuki, Naoko Inomata, Atsushi Fukunaga, Guenther Kaiser, Junyi Wang, Soichiro Matsushima, Steven Greenberg, Sam Khalil   +10 more
doaj   +1 more source

Optimising the Diagnosis of Sesame Seed Allergy With the Basophil Activation Test

Allergy, EarlyView.
The basophil activation test (using the activation marker CD203c) was the only test able to both exclude and confirm sesame seed allergy with precision. A negative skin prick test to sesame extract or tahini and undetectable IgE to Ses i 1 could not rule out sesame seed allergy.
Ru‐Xin Foong, Irene Bartha, Holly Boyd, Andreina Marques‐Mejias, Suzana Radulovic, Marta Krawiec, Faye Harrison, Malak Eghleilib, Grammatiki Antoneria, Zainab Jama, Matthew Kwok, Vasco Claro, Cristian Ricci, Tom Marrs, Gideon Lack, George Du Toit, Alexandra F. Santos   +16 more
wiley   +1 more source

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Risk Management and Healthcare Policy, 2020
Giorgio Walter Canonica, 1 Giorgio Lorenzo Colombo, 2, 3 Paola Rogliani, 4 Pierachille Santus, 5 Claudia Pitotti, 6 Sergio Di Matteo, 3 Chiara Martinotti, 3 Giacomo Matteo Bruno 3 1Asthma & Allergy Clinic, Humanitas University, Milan, Italy; 2S.A.V.
Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM   +7 more
doaj  

Kinetics of Antibody Responses and Effector Cell Sensitivity After High Dose Birch Extract Nasal Challenge

Allergy, EarlyView.
High‐dose birch‐extract nasal challenge induced synchronous peaks at 4 weeks in serum specific IgE (sIgE) and basophil sensitivity. Mast cell sensitivity via tSPT and sIgG1 and sIgG4 responses peaked later, at 6–8 weeks. Preseasonal allergen exposure attenuated seasonal sIgE increase and prevented further rise in tSPT sensitivity.
N. J. Campion, S. Villazala‐Merino, C. Morgenstern, L. Nemec, V. Stanek, A. Tu, M. Zghaebi, J. Toth, R. Fröschl, T. Perkmann, M. Bastl, K. Gangl, S. Schneider, H. Breiteneder, R. Ristl, M. Focke‐Tejkl, R. Valenta, V. Niederberger‐Leppin, J. Eckl‐Dorna   +18 more
wiley   +1 more source